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Abstract: Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved 
for the treatment of non-small cell lung cancer (NSCLC) in 2003 in the US. Activating EGFR 
  mutations were subsequently discovered in 2004, and heralded the era of molecular targeted 
therapy in NSCLC. The discovery of anaplastic lymphoma kinase (ALK) rearrangement in 
NSCLC in 2007 by two independent groups not only represents the first time ALK rearrangement 
has been discovered in common solid tumors but also represents another important milestone in 
the era of molecular targeted therapy in NSCLC. Crizotinib, a mesenchymal-epithelial transition 
(MET)/ALK multi-targeted receptor tyrosine kinase inhibitor went into early Phase I clinical 
development in 2007. Using the knowledge that NSCLC patients with activating EGFR muta-
tions benefited from EGFR tyrosine kinase inhibitors, crizotinib was rapidly and successfully 
developed as an inhibitor in ALK-rearranged NSCLC, based on a break apart fluorescence 
in situ hybridization assay, developed by two of the crizotinib Phase I sites. It cumulated in 
the conditional approval of crizotinib by the US Food and Drug Administration on August 26, 
2011 for the treatment of ALK-rearranged NSCLC. The conditional approval was based on   
response rates of 50% and 61% from 255 ALK-rearranged NSCLC patients enrolled in two 
single-arm trials. Common adverse events of crizotinib include mild transient visual disorders, 
mild gastrointestinal toxicities, fatigue, rare alanine transaminase elevations, and even rarer 
pneumonitis (1.6%). Confirmatory trials comparing crizotinib with standard chemotherapy 
are ongoing. It took an unprecedented four years from the discovery of ALK rearrangement in 
NSCLC to the approval of crizotinib, the first ever ALK inhibitor, for the treatment of ALK-
rearranged NSCLC.
Keywords: crizotinib, PF-02341066, anaplastic lymphoma kinase (ALK), rearrangement, 
non-small cell lung cancer
Introduction
During the past few years, the seminal discovery of activating mutations in the kinase 
domain of the epidermal growth factor receptor (EGFR) gene has revolutionized the 
treatment of non-small cell lung cancer (NSCLC).1–3 While the first EGFR tyrosine 
kinase inhibitors (gefitinib, erlotinib) were approved for use in NSCLC prior to 
the knowledge of activating EGFR mutations,4,5 the clinical utility of EGFR tyrosine 
kinase inhibitors has been optimized after the discovery of EGFR mutations and 
heralded the era of molecular targeted therapy in NSCLC. Retrospective analysis of 
IPASS (Iressa Pan-Asia Study) clearly demonstrated that the presence or absence of Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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EGFR mutations in Asian never-smokers/light former smok-
ers significantly determines the presence or lack of response 
to EGFR tyrosine kinase inhibitors, respectively.6,7 Several 
prospective randomized trials have now confirmed the use of 
EGFR tyrosine kinase inhibitors in patients with advanced 
treatment-naïve NSCLC with EGFR mutations significantly 
improved the response rate and progression-free survival 
compared with standard platinum-based chemotherapy.8–11 
The characterization of NSCLC patients with activating 
EGFR mutations provided the bulk of the molecular under-
pinning of the seminal observation that NSCLC in never-
smokers (,100 cigarettes lifetime) is a distinct clinical entity 
(higher proportion of adenocarcinoma, female, Asian, better 
survival).12 However, as demonstrated by IPASS, even among 
a clinically defined NSCLC patient cohort (Asian, female, 
adenocarcinoma, never-smokers) only slightly more than 
half of these patients harbored activating EGFR mutations 
and that other “driver mutations “ remained to be discovered 
in NSCLC.6,7
Anaplastic lymphoma kinase (ALK) is thus named 
because it was first discovered to be translocated in anaplastic 
large cell lymphoma.13 Since the late 1980s, alterations in the 
ALK gene have been well recognized as playing a key role in 
the pathogenesis of anaplastic large cell lymphoma, a subset 
of B cell non-Hodgkin’s lymphoma, inflammatory myofibro-
blastic tumors, and in neuroblastoma.14 However, perturba-
tions in the ALK gene had not been found in common solid 
tumors until two groups independently reported the discovery 
of ALK rearrangement in NSCLC in 2007.15,16 Soda et al 
screened a cDNA library derived from adenocarcinoma of the 
lung of a 62-year-old male Japanese smoker for transforming 
activity.15 This fusion arises from an intrachromosomal inver-
sion on the short arm of chromosome 2 [Inv (2)(p21p23)] that 
joins exons 1–13 of the echinoderm microtubule-associated 
protein-like 4 gene (EML4) to exons 20–29 of ALK. The 
resulting chimeric protein, EML4-ALK, contains an N ter-
minus derived from EML4 and a C terminus containing the 
entire intracellular tyrosine kinase domain of ALK. Since 
the initial discovery of this fusion, multiple other variants of 
EML4-ALK have been reported, all of which encode the same 
cytoplasmic portion of ALK but contain different truncations 
of EML4.17,18 Additionally, other fusion partners with ALK 
have been described (TFG and KIF5B), but these fusion 
variants are much less common than EML4-ALK.17,18 The 
various fusion partners of ALK mediate ligand-independent 
dimerization of ALK resulting in constitutive kinase   activity. 
EML4-ALK possesses potent oncogenic activity in cell cul-
tures.15 In transgenic mouse models, lung-specific   expression 
of EML4-ALK leads to development of numerous lung 
adenocarcinoma.19 Treatment of EML4-ALK transgenic 
mice with ALK inhibitors also results in tumor regression.19   
Contemporaneously, Rikova et al independently discovered 
the same EML4-ALK translocation in NSCLC while search-
ing for candidate tyrosine kinases in NSCLC by screening 
for phosphotyrosine activation in 150 NSCLC tumors as well 
as 41 NSCLC cell lines.16 They identified kinases known 
to have a dominant role in NSCLC pathogenesis, such as 
EGFR and mesenchymal-epithelial transition (MET) receptor 
tyrosine kinase, as well as others not previously implicated in 
NSCLC, including platelet-derived growth factor receptor-α 
and ROS. The samples with ALK hyperphosphorylation were 
shown to harbor   EML4-ALK (three cases) or TFG-ALK 
(one case).16
ALK belongs to the leukocyte tyrosine kinase recep-
tor superfamily. ALK is a single-chain transmembrane 
receptor. The extracellular domain contains an N-terminal 
signal peptide sequence and is the ligand-binding site for 
the activating ligands of ALK, pleiotrophin, and midkine. 
This is followed by the transmembrane and juxtamembrane 
region which contains a binding site for phosphotyrosine-
dependent interaction with insulin receptor substrate-1. The 
final section has an intracellular tyrosine kinase domain with 
three phosphorylation sites (Y1278, Y1282, and Y1283), 
followed by the C-terminal domain with interaction sites 
for phospholipase C-gamma and Src homology 2 domain-
containing SHC. The signaling pathways involving ALK 
have recently been the subject of an expert review.20
Simultaneous with the discovery of ALK-rearranged 
NSCLC, crizotinib, a multitargeted receptor tyrosine kinase 
inhibitor, entered early Phase I clinical development   primarily 
as a MET inhibitor. With the ability of a few Phase I clinical 
sites to develop and standardize a breakapart fluorescence 
in situ hybridization (FISH) assay for ALK-rearranged 
NSCLC, there was a concerted switch in the focus of the 
Phase I crizotinib trial when the first two ALK-rearranged 
NSCLC patients derived clinical benefit from crizotinib.
This review summarizes the preclinical and clinical data 
that led to conditional approval of crizotinib by the US Food 
and Drug Administration (FDA). It will discuss the advan-
tages and limitations of the breakapart FISH assay as the 
companion diagnostic approved by the FDA for the detection 
of ALK-rearranged NSCLC that accompanied the approval 
of crizotinib. This review will also examine newer agents 
(second-generation ALK inhibitors, heat shock protein [Hsp] 
90 inhibitors) that can potentially overcome the resistance 
to crizotinib that has already been discovered, and touches Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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upon other tumors and receptor tyrosine kinases that may be 
inhibited by crizotinib.
Chemistry and pharmacology
Crizotinib (previously known as PF02341066, marketed as 
XalkoriTM, Pfizer, New York, NY) was synthesized primarily 
as a MET inhibitor. It was engineered based on interactions 
of PHA-665752, a potent MET inhibitor, at the ATP-binding 
sites of the MET kinase domain obtained from the cocrystal 
structure of PHA-665752 binding in the MET kinase domain. 
Binding of PHA-665752 to the MET kinase domain results 
in displacement of the kinase activation loop that interferes 
with ATP and substrate binding to the MET receptor tyrosine 
kinase. PHA-665752 is a powerful dose-dependent MET 
inhibitor in cell lines and in xenograft models. However, 
the low solubility of PHA-665752 at pH 7.4, its high meta-
bolic clearance, and its poor permeability limit its ability 
as a clinical MET inhibitor. Crizotinib was designed using 
a structure-based drug design program to be less lipophilic 
and have a small hinge binder to allow better interaction in 
the kinase pocket (Figure 1).21
Crizotinib was evaluated against a panel of more than 120 
kinases in biochemical assays and twelve cell-based phospho-
rylation assays, and was determined to be nearly 20-fold more 
selective for ALK and MET compared with other kinases 
evaluated. Crizotinib inhibited nucleophosmin (NPM)-ALK 
phosphorylation in Karpas299 or SU-DHL-1 anaplastic large 
cell lymphoma cells (mean IC50 value, 24 nmol/L), and inhib-
ited cell proliferation and induced apoptosis in NPM-ALK-
dependent Karpas299 or SU-DHL-1 cell lines. Furthermore, 
crizotinib also inhibited ALK phosphorylation and growth in 
a NPM-ALK-dependent Karpas299 tumor xenograft model. 
Crizotinib potently inhibited cell proliferation, which was 
associated with G1-S phase cell cycle arrest and induction 
of apoptosis in ALK-positive anaplastic large cell lymphoma 
cells (IC50 values, about 30 nmol/L). Oral administration of 
crizotinib to severe combined immunodeficient-beige mice 
bearing Karpas299 anaplastic large cell lymphoma tumor 
xenografts resulted in dose-dependent antitumor efficacy, 
with complete regression of all tumors at the 100 mg/kg/day 
dose within 15 days of initial administration of the com-
pound. A strong correlation was observed between antitumor 
response and inhibition of NPM-ALK phosphorylation and 
induction of apoptosis in tumor tissue. In addition, inhibition 
of key NPM-ALK signaling mediators, including phospholi-
pase C gamma, STAT3, and Akt, by crizotinib was observed 
at concentrations or dose levels that correlated with inhibition 
of NPM-ALK phosphorylation and function.22
First in-human Phase I  
trial of crizotinib
The first in-human Phase I trial of crizotinib (A8081001, 
NCT00585195) trial was designed as an open-label, multi-
center two-part trial that was activated in 2006. The first part 
was the standard dose-escalation finding schema to determine 
the maximal tolerated dose and the recommended Phase II 
dose. There was also a single day -7 dose to establish the 
single-dose pharmacokinetics. Crizotinib was first dosed at 
50 mg orally once daily and subsequently escalated to 300 mg 
orally twice daily at which two patients experienced grade 
three fatigue. The dose of crizotinib was eventually reduced to 
250 mg orally twice daily and was found to be tolerable and 
was determined to be the maximal tolerated dose and recom-
mended Phase II dose.23 There was also a substudy to inves-
tigate the effect of food on crizotinib level and a midazolam 
substudy to assess the effect of cytochrome P450 (CYP) 3A 
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Figure 1 Synthesis and structure of crizotinib. The hinge binder 2 aminopyridine in crizotinib is highlighted in red. The molecular formula for crizotinib is C21H22Cl2FN5O. 
The molecular weight is 450.34 Da. The chemical name for crizotinib is (R)-3-[1-(2,6-Dichloro-3-fluorophenyl)-ethoxy]-5-[(1-piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine.
Figure provided by Dr Jean Cui.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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isozyme inhibition by crizotinib. In contrast with other 
Phase I trials, the efficacy data from prospective enrollment of 
ALK-rearranged NSCLC patients into this Phase I crizotinib 
trial was used in part to obtain conditional FDA approval. 
Therefore, a lot of data on pharmacokinetics, efficacy, and 
adverse events were generated from this one Phase I trial.
Pharmacokinetics
Eleven patients were enrolled into the food effect sub-
study. There was no food effect on the pharmacokinetics 
of   crizotinib. The absorption of a single 250 mg dose of 
crizotinib after a high-fat, high-calorie meal did not differ 
from the concentration of a single 250 mg dose of crizotinib 
taken on an empty stomach.24 The peak plasma concentra-
tion was reached 4 hours after a single dose of crizotinib. 
Pharmacokinetics were linear from a 100 mg once daily dose 
to a 300 mg twice daily dose.23,24 A steady-state concentra-
tion of crizotinib was reached after 15 days of repeated 
administration of crizotinib 250 mg orally twice a day, with 
a half-life of around 43–51 hours.24 The mean steady-state 
trough plasma level for crizotinib 250 mg taken twice a day 
(the recommended Phase II dose) was 274 ng/mL or 57 nM of 
free drug, which exceeded the target efficacy levels predicted 
for the inhibition of MET (about 13 nM) and ALK (about 
26 nM) based on preclinical mouse models.24
Thirteen patients were enrolled in the midazolam substudy. 
The pharmacokinetics of a single 2 mg midazolam dose was 
evaluated before and 28 days after crizotinib 250 mg adminis-
tered orally twice a day. Midazolam is metabolized by CYP3A 
isozymes. There was a 3.6-fold increase in the midazolam level 
(90% confidence interval 2.7–4.9) after 28 days of 250 mg 
twice a day of crizotinib, indicating that crizotinib is a moderate 
CYP3A inhibitor.24 Crizotinib is also predominantly metabo-
lized by the CYP3A isozymes in human microsomes. The total 
clearance of crizotinib from plasma was lower after 250 mg 
twice a day than after a single 250 mg dose (100 L/hour), 
likely due to the autoinhibition of CYP3A.24 The cerebral 
spinal fluid to plasma ratio of crizotinib was measured and 
reported to be 0.0026 in a ALK-rearranged NSCLC patient.25 
The low crizotinib level in the cerebral spinal fluid implies poor 
blood-brain barrier penetration of the drug. However, this is 
the only report of the level of crizotinib achieved in cerebral 
spinal fluid in one patient.
Clinical efficacy
Crizotinib was initially developed as a MET inhibitor, and the 
second part of the protocol called for screening of patients 
with tumors that harbor MET amplification   (non-Barrett’s 
gastroesophageal junction cancer, gastric cancer,) or MET 
mutations (lung cancer in former/current smokers, squamous 
cell carcinoma of the head and neck, papillary renal cell 
carcinoma) to enroll into the molecularly enriched cohort 
part of the protocol. Other rare tumors that may also be 
involved in the MET signaling pathway, such as alveolar 
soft part sarcoma and alveolar rhabdomyosarcoma were also 
eligible upon histological confirmation. However, during the 
dose-escalation phase, ALK rearrangement in NSCLC was 
discovered and one of the clinical sites involved in A8081001 
was in the process of developing a breakapart FISH assay to 
detect ALK rearrangement in tumors. The first EML4-ALK 
NSCLC patient enrolled in the trial was a 49-year-old male 
never-smoker enrolled onto the 300 orally twice a day cohort 
on December 26, 2007 at Massachusetts General Hospital, 
Boston, MA, barely 4 months after publication of the Soda 
et al paper. He had a dramatic clinical response within weeks, 
but developed liver enzyme elevation and had to be taken 
off treatment. The second ALK-rearranged NSCLC patient 
was a 30-year-old male never-smoker enrolled into the trial 
at Beth Israel Deaconess Medical Center, Boston, MA on 
June 5, 2008, onto the 200 mg orally twice a day cohort and 
achieved stable disease for several months. He eventually 
developed brain metastasis. After radiation to the brain, his 
crizotinib dose was increased to 250 mg orally twice a day 
but he had disease progression after 1 month.25 Because both 
ALK-rearranged NSCLC patients had dramatic improvements 
in symptoms, this prompted the protocol to be amended to 
allow a large-scale prospective screening for ALK-rearranged 
NSCLC among the seven participating clinical sites and nine 
participating hospitals. Screening for patients with MET-
amplified or MET-mutated tumors continued simultaneously. 
The main eligibility for the ALK molecular-enriched cohort 
was that patients had to be tumor-positive for ALK rearrange-
ment by FISH. Other common eligibility criteria include 
Eastern Cooperative Oncology Group performance status 
0–2. Patients with stable brain metastasis or patients on stable 
coagulation were eligible. There was no limit on the number of 
previous treatment regimens for any patient. Patients enrolled 
onto the ALK or MET enriched molecularly defined portion 
of the trial were evaluated for safety at least once every two 
weeks during the first two cycles (one cycle is 28 days) and 
then at least every four weeks thereafter. Radiological assess-
ments were performed at baseline and generally after every 
two cycles of treatment using the Response Evaluation Criteria 
in Solid Tumors (RECIST) version 1.0. Adverse events were 
reported according to the National Cancer Institute’s Common 
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Initially, there was no screening strategy for ALK-
rearranged NSCLC patients, but as more and more ALK-
rearranged NSCLC patients were identified it became clear 
that ALK-rearranged NSCLC patients generally present 
with adenocarcinoma (with the presence of signet ring cell 
features within the adenocarcinoma), are never-smokers, 
are younger than the general NSCLC population, and har-
bor wild-type EGFR.18 The efficacy results for crizotinib 
in the first 19 patients with ALK-rearranged NSCLC were 
presented in 2009.23 There were ten responders out of 
the first 19 patients (overall response rate, 53%) and five 
additional patients had achieved stable disease, giving a 
disease control rate (overall response rate + stable dis-
ease) of 79%. Subsequent efficacy results for crizotinib 
in 82 ALK-rearranged NSCLC patients were published 
in 2010.26 The overall confirmed response rate was 57% 
(1% complete response + 56% partial response) and an 
additional 33% of patients achieved stable disease for a 
disease control rate of 90%. Of note, 87% disease control 
rate was achieved at eight weeks (two cycles, Figure 2). 
All of the ALK-rearranged NSCLC patients also screened 
negative for MET amplification. The mean duration of 
treatment was 6.4 months with ongoing follow-up, and 
the estimated probability of progression-free survival 
at 6 months was estimated at 72%. In a subset of ALK-
rearranged patients where the fusion partners were able 
to be identified by reverse transcription polymerase chain 
reaction (PCR), there was a difference in efficacy among 
the different EML4-ALK fusion product.26 In 2011, results 
of crizotinib on 119 ALK-rearranged NSCLC patients 
were presented.27 These 119 patients were combined with 
136 ALK-rearranged NSCLC patients from another trial 
and constituted the efficacy data that formed the basis for 
the conditional approval of crizotinib. The clinicopatho-
logic characteristics of these 255 patients were listed in 
Table 1. Among the 119 patients, the median age is 51 years   
Figure 2 Response of ALK-rearranged NSCLC after 2 months of crizotinib.
Table 1 Clinicopathologic characteristics of 255 patients with 
ALK-rearranged  NSCLC,  the  data  for  whom  were  used  for 
conditional approval of crizotinib27,29
Patient characteristics (n = 255)
Median (range) age (years) 51 (21–82)
Gender (%)
  Male 
  Female
123 (48) 
133 (52)
eastern Cooperative Oncology Group performance status (%)
 0  
 1  
  2–3
78 (30) 
137 (54) 
40 (16)
Race (%)
  Caucasian 
  African-American 
  Asian 
  Other
161 (63) 
8 (3) 
77 (30) 
9 (4)
Smoking status (%)
  Never-smoker 
  Former smoker 
  Current smoker
178 (70) 
71 (28) 
6 (2)
Histology (%)
  Adenocarcinoma 
  Squamous cell carcinoma 
  Large cell carcinoma 
  Adenosquamous carcinoma 
  Other
246 (96.5) 
2 (1) 
1 (0.5) 
3 (1) 
3 (1)
Disease stage (%)
  Locally advanced 
  Metastatic
14 (5.5) 
241 (94.5)
Number of prior regimens of systemic therapy (%)
 0  
 1  
 2  
 3  
  $4
15 (6) 
47 (18) 
57 (22) 
54 (21) 
82 (32)
and equally divided between female and male, 72% were 
never-smokers, and 97% had adenocarcinoma histology. 
The response rate is 61% (Table 2) with an estimated 
progression-free survival of about 10 months (95% confi-
dence interval 8.2–14.7) and median overall survival has 
not been reached as only 19% of the patients have died. 
Table 2 Efficacy of 255 patients with ALK rearranged non-small 
cell lung cancer enrolled in A8081001 and PROFiLe 100527,29
Efficacy parameter A8081001 
(n = 119*)
PROFILE 1005   
(n = 136)
ORR (CR + PR)  
[% (95% CI)]
61% (2% + 59%)  
[52%, 70%]
50% (1% + 49%)  
[42%, 59%]
Duration of response  
(months) [range]
11.22 (0.96–17.87) 9.78 (1.45–9.82)
Notes:  *119  patients  enrolled  and  116  evaluable  patients.  Response  rate  was 
calculated based on 116 patients. 
Abbreviations: CR, complete response; ORR, overall response rate; PR, partial 
response.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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The median duration of response is 48 weeks at the time of 
data cutoff.27 Median time to response is 8 weeks which is 
essentially at the follow-up diagnostic scan. Indeed, some 
of the patients achieved symptomatic relief and significant 
tumor shrinkage within days of starting crizotinib (Fig-
ure 3).28 The efficacy of crizotinib has been remarkably 
consistent since the efficacy of the first 19 ALK-rearranged 
NSCLC patients was reported, and has cemented confi-
dence among oncologists about the efficacy of crizotinib 
in ALK-rearranged NSCLC patients while the confirmatory 
randomized trials are being done.
Phase II trial of ALK-rearranged 
NSCLC
The Phase II trial of ALK-rearranged NSCLC (PROFILE 
1005, NCT00932451) was originally designed as an open-
label, single-arm study of the efficacy and safety of crizotinib 
in ALK-rearranged NSCLC who had failed more than two 
lines of chemotherapy. It serves as a compendium trial to the 
second-line randomized trial (PROFILE 1007) for patients 
who were randomized to and progressed on the chemotherapy 
arm of PROFILE 1007. PROFILE 1007 does not allow 
patients on the chemotherapy arm to crossover to crizotinib 
after disease progression. Instead, these patients are to enrol 
into PROFILE 1005.
In anticipation of the approval of crizotinib in the US, 
PROFILE 1007 was closed to accrual for patients in the US 
in order to protect the integrity of the trial because Pfizer 
anticipates patients on the chemotherapy arm may decide to 
take crizotinib off trial once it is approved. In conjunction 
with the closure of PROFILE 1007 in the US, major amend-
ments were made to PROFILE 1005 to allow ALK-rearranged 
patients identified during the screening period of PROFILE 
1007 to enroll without having progressed on chemotherapy. 
Other changes in the criteria for enrollment included patients 
with nonmeasurable disease who were allowed to enroll. 
However, the major change to the protocol was that patients 
who tested positive for ALK rearrangement other than by the 
breakapart FISH assay performed at the central laboratory 
were allowed to enroll on a “case by case” basis. Therefore, 
ALK rearrangement detected by immunohistochemistry 
(IHC), reverse transcription PCR, or breakapart FISH per-
formed at commercial laboratories were potentially able to 
enroll into A8081005, essentially turning A8081005 into an 
expanded access program prior to the approval of crizotinib 
in August 2011.
The efficacy results for the first 136 ALK-rearranged 
NSCLC patients from PROFILE 1005 were presented 
in 2011.29 The response rate was 50% at the time of data 
cutoff (Table 2). The efficacy data from these 136 patients 
together with the 119 ALK-rearranged NSCLC patients from 
A8081001 formed the basis of the FDA conditional approval 
of crizotinib in the US. The clinicopathologic characteristics 
of these 255 patients are listed in Table 1.
Day −7 Day +14
Patient
Figure 3 Dramatic response to crizotinib in a ALK-rearranged NSCLC patient.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Phase III trials of ALK-rearranged 
NSCLC
Currently there are two ongoing randomized Phase III trials 
comparing crizotinib and chemotherapy. PROFILE 1014 
(NCT01154140) is comparing crizotinib with platinum-
  pemetrexed combination chemotherapy in previously untreated 
patients with advanced ALK-rearranged adenocarcinoma of the 
lung. The primary endpoint is progression-free survival, and 
patients randomized to chemotherapy are allowed to cross over 
to crizotinib on disease progression. Breakapart FISH assay is 
the companion diagnostic test to detect ALK rearrangement. 
PROFILE 1007 (NCT00932451) is comparing crizotinib with 
pemetrexed or docetaxel in the second-line setting in patients 
with ALK-rearranged adenocarcinoma of the lung. The primary 
endpoint is progression-free survival. While the trial has been 
closed to accrual in the US as discussed above, accrual is still 
ongoing in the rest of the world.
Adverse events
Adverse events are tabulated together for the 255 ALK-
rearranged NSCLC patients enrolled in A8081001 and 
PROFILE 1005 (Table 3). Most of the adverse events are 
Table  3  Treatment-related  adverse  events  in  .10%  of  255 
patients with ALK rearranged non-small cell lung cancer treated 
on trials A8081001 and PROFiLe 100527,29
Adverse event Treatment-related
All grades n (%) Grade 3–4 n (%)
eye disorders* 159 (62%) 0
Gastrointestinal disorders
  Nausea 
  Diarrhea 
  vomiting 
  Constipation 
  esophageal disorder**
136 (53%) 
109 (43%) 
101 (40%) 
69 (27%) 
29 (11%)
0 
0 
0 
1 (,1%) 
0
General
  edema 
  Fatigue 
  Decreased appetite
72 (28%) 
51 (20%) 
49 (19%)
0 
4 (2%) 
0
Nervous system disorder
  Dizziness 
  Neuropathy 
  Dysgeusia
42 (16%) 
34 (13%) 
30 (12%)
0 
1 (,1%) 
0
Liver disorders
    Alanine transaminase  
increase
34 (13%) 14 (5%)
Skin disorders
  Rash 25 (10%) 0
Notes: *Includes photopsia, diplopia, photophobia, blurred vision, visual field defect, 
visual impairment, vitreous floaters, visual brightness, and reduced visual acuity; 
**includes  dyspepsia,  dysphagia,  epigastric  discomfort/pain/burning,  esophagitis, 
esophageal obstruction/pain/spasm/ulcer, gastroesophageal reflux, odynophagia, and 
reflux esophagitis.
mild (grade 1–2). Both trials are ongoing, and adverse events 
as well as efficacy data should be updated with further 
publications. The most common adverse event is a visual 
disorder consisting primarily of light flashes in the periph-
eral visual field during light transition (from dark to light or 
vice versa). These visual abnormalities are usually transient, 
lasting seconds and generally decreasing in frequency with 
prolonged crizotinib use. Repeat visual acuity and slit lamp 
examination were negative. The visual disorders disappeared 
after discontinuation of crizotinib. The vast majority of the 
patients were not bothered by these “visual disturbances”. 
PROFILE 1007 and 1014 are prospectively collecting data 
on these visual disturbances by questionnaire.
Other common adverse events were mild (grade 1–2) 
gastrointestinal in nature (nausea, vomiting, constipation, or 
diarrhea). Diarrhea was generally mild and on average not 
as severe as diarrhea from epithelial growth factor receptor 
(EGFR) tyrosine inhibitors. Nausea and vomiting can be 
mitigated by food so it is recommended that crizotinib should 
not be taken on an empty stomach. Food has a minimal effect 
on the level of crizotinib. Dysgeusia (taste change) occurred 
in 12% of the patients and is different from the usual lack 
of taste or metallic taste that are generally associated with 
other medications. Patients described a hypersensitivity to 
or accentuation of sweet or sour taste sensations while the 
taste for hot or spicy food is diminished.
Critical appraisal of adverse events
Three adverse events warranted “warnings and precautions” in 
the package insert, ie, pneumonitis, hepatic laboratory abnor-
malities, and QT interval prolongation.30 Treatment-related and 
potential life-threatening pneumonitis occurred in four of 255 
patients (1.6%) and all within two months of starting crizo-
tinib.30 It will be important to determine if there are risk factors 
for developing pneumonitis on crizotinib according to gender, 
ethnicity, comorbidities, smoking   history, and prior radiation.
Serial electrocardiograms in triplicate two minutes apart 
were obtained following a single dose and then at steady-state 
to assess the QT interval prolongation potential of crizo-
tinib in all patients (n = 308) who received 250 mg orally 
twice a day. Four of 308 (1.3%) were found to have a QTcF 
  (corrected QT by Fridericia method: QTcF = QT⁄3√response 
rate) .500 msec.30 However, the incidence of QTcF in the 
255 patients with ALK-rearranged NSCLC have not been 
reported.27,29 Furthermore, QTcF was not associated with the 
dose level of crizotinib.31
Grade 1–2 sinus bradycardia has been reported in 12 of 255 
patients (5%) so far. Bradycardia is a pharmacodynamic effect Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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of crizotinib. It has been reported that there was a decrease 
of heart rate of 2.5 beats per minute for every 100 mg/mL of 
crizotinib.31 Indeed, several patients who received prolonged 
crizotinib developed asymptomatic but profound (heart rate 
#45) sinus bradycardia without an increase in the PR inter-
val or QTc prolongation.32 It will be important to determine 
the pharmacokinetics of crizotinib in patients who develop 
profound sinus bradycardia, to see if there is any correlation 
between overall response rate and the degree of bradycardia, 
given that bradycardia is a pharmacodynamic phenomenon 
with crizotinib. It will also be important to determine if there 
are any correlations between age, gender, length of treatment, 
ethnicity, and profound sinus bradycardia, given that Asian 
patients achieved, on average, a 40%–50% higher crizotinib 
level than Caucasian patients.33
What is the best companion 
diagnostic test for ALK 
rearrangement?
The paradigm of molecularly targeted therapy in oncology 
depends critically on a validated test to provide a uniform 
platform for detecting the molecular alteration in question. 
The test has to be both highly sensitive and specific, yet 
relatively inexpensive and not highly technical to perform to 
enable widespread adoption and implementation of the para-
digm, especially in developing countries so that the maximum 
number of patients can be identified to benefit from treat-
ment. Breakapart FISH assay is the companion diagnostic 
test approved by the FDA to detect ALK-rearranged NSCLC 
in conjunction with conditional approval of crizotinib in the 
US. Two major criteria have to be satisfied for a sample to 
be positive for ALK rearrangement. First, more than 15% of 
the cells counted have to harbor signals that indicate ALK 
translocation, ie, separation of the 5′ (green color) and 3′ 
(red color) has to be greater than 2 signal diameter in length, 
OR the presence of’ signal (red color) alone. Second, at least 
50 cells have to be counted (Table 4). These two criteria 
were developed by Dr Anthony John Iafrate’s laboratory at 
  Massachusetts General Hospital and later validated by Dr 
Marileila   Varella-Garcia at the University of Colorado Denver 
Cancer Center. Camidge et al reported that in ALK rearrange-
ment-positive NSCLC, the mean percentage of positive cells 
for breakapart FISH was 53.8% (range 22.25%–86.62%), 
while in ALK rearrangement-negative NSCLC, the mean 
percentage of positive cells for breakapart FISH was 5.98% 
(range 3.51%–9.45%; P . 0.0001).34 Furthermore, counting 
45 nuclei will give .99% sensitivity and 100% specificity, 
while counting 60 cells will give 100% sensitivity and 100% 
specificity.34
There are advantages and disadvantages to using the 
breakapart FISH assay. Breakapart FISH is the assay used 
to identify patients with ALK-rearranged NSCLC to enroll 
them prospectively into crizotinib trials and thus is the only 
assay validated to correspond with the response to crizotinib. 
Breakapart FISH does not depend on knowing all the fusion 
partners to ALK since some of the fusion partners to ALK 
in NSCLC may remain to be discovered. Breakapart FISH 
can be performed on formalin-fixed paraffin-embedded 
  tissue, which is how the vast majority of lung cancer tissue 
is processed. On the other hand, the breakapart signal pattern 
resulting from intrachromosomal deletions and inversion 
events occurring in the setting of polysomy typical of lung 
cancer is subtle and can easily be missed. Thus, to interpret 
the ALK breakapart FISH assay requires experience, patience, 
precise measurements (.2 signal diameter separation), and 
technical expertise. Furthermore, breakapart FISH assay is 
expensive. Therefore, breakapart FISH is unlikely to be the 
preferred method to screen for ALK rearrangement of NSCLC 
in routine surgical pathology practice, thereby limiting the 
utility of breakapart FISH assay as a screening test.
A second assay to detect ALK rearrangement is reverse 
transcriptase-PCR.35 Reverse transcriptase-PCR is relatively 
easy to perform in most laboratories worldwide. Second, 
the fusion partners to ALK must be known. Knowledge of 
the fusion partners will be important in the future to subdi-
vide ALK-rearranged NSCLC into different fusion partners 
in terms of their clinicopathologic characteristics and natural 
history and potential response to ALK inhibitors. The disad-
vantage of reverse transcriptase-PCR is that RNA may not be 
well preserved in formalin-fixed paraffin-embedded tissues to 
allow a successful reverse transcriptase-PCR reaction. More 
importantly, in order not to miss any ALK rearrangement, all 
the know fusion partners for ALK have to be known in order 
for the PCR reaction to include primers for all the ALK fusion 
genes. Finally, reverse transcriptase-PCR requires more tumor 
tissue material than breakapart FISH and, unfortunately, in an 
Table 4 Criteria for breakapart fluorescence in situ hybridization 
positivity for detection of ALK-rearranged non-small cell lung cancer
Characteristics Criteria for positivity
Number of cells counted At least 50 cells
Percentage of positive signals .15%
Distance between 5′ (green) and 3′ (red)  
ALK signals 
Presence of single 3′ ALK (red) signal only 
Presence of single 5′ ALK (green) signal only
Greater than two signal 
diameter separation 
Yes 
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era of molecularly targeted lung cancer treatment, the amount 
of tumor biopsied for diagnosis is still relatively small and 
frequently inadequate for molecular profiling.
A third screening test for ALK-rearranged NSCLC is 
immunohistochemistry (IHC). The ALK protein is gener-
ally not expressed in most normal tissues and its presence 
in a tumor specimen could be sufficiently abnormal as 
to indicate an oncogenic role in those cells. Currently, a 
commercially available ALK1 antibody (Dako, Glostrup, 
Denmark) is being used to detect ALK rearrangement in 
anaplastic large cell lymphoma. However, expression of 
ALK protein in ALK-rearranged NSCLC is at least five-
fold lower than ALK protein expression in anaplastic large 
cell lymphoma, likely due to weaker transcriptional activity 
of the promoter-enhancer region of EML4 that drives the 
expression of EML4-ALK compared with that of the NPM 
promoter involved in the NPM-ALK fusion protein in ana-
plastic large cell lymphoma.36 It has been demonstrated that 
in order to increase the sensitivity of ALK1 antibodies in 
detecting ALK rearrangement in NSCLC, the increased titer 
of ALK1 used leads to nonspecific staining of nontumor tis-
sue, leading to decreased specificity (high false positive rate). 
Alternatively, in conditions that allow for 100% specificity 
(no false positives), the detection rate of ALK1 is greatly 
compromised (32%).36 Several monoclonal antibodies are 
in development. D5F3 (Cell Signaling Technology, Beverly, 
MA), a newer and more specific antibody to ALK, was shown 
to have 100% sensitivity and 99% specificity, with a positive 
predictive value of 96% and negative predictive value of 
100%, with excellent interobserver reproducibility of 94% 
(κ = 0.94).36 In the same study, ALK1 only had a sensitivity 
of 67%, specificity of 97%, a positive predictive value of 
78%, a negative predictive value of 95%, and κ = 0.74.36
Two separate studies have compared IHC using ALK137 
with another new antibody in development 5A4   (Novocastra, 
Newcastle, UK),38 with the breakapart FISH assay (Table 5). 
The results indicated that while IHC 3+ or IHC 0 from both 
antibodies had perfect concordance with FISH, a few IHC 
2+ or IHC 1+ patients were also positive for FISH. Thus, 
algorithms have to be developed in these intermediate IHC 
staining cases so that all ALK-positive patients can be identi-
fied because of the low prevalence of ALK rearrangement in 
NSCLC, even a few missed cases represent a significant pro-
portion of all ALK rearranged NSCLC. Comparison of IHC, 
reverse transcription PCR, and FISH has been performed in 
anaplastic large cell lymphoma, and IHC with ALK performs 
similarly to FISH, while reverse transcription PCR is not as 
sensitive.39 Thus, when these newer ALK antibodies become 
commercially available, they will likely allow mass screening 
for ALK rearrangement in NSCLC because IHC is easy to 
perform and interpret and is cost-effective. However, vali-
dation studies of IHC using the newer antibodies compared 
with FISH similar to what has been performed for anaplastic 
large cell lymphoma39 will have to be performed before IHC 
is officially considered as a companion diagnostic assay for 
ALK-rearranged NSCLC.
Table 5 Comparison of immunohistochemistry using various ALK antibodies and fluorescence in situ hybridization
Mayo study: IHC (ALK1) versus FISH study (κ = 0.55)37 
(12 ALK FISH positives out of 103 NSCLC tumors screened)
IHC 3+ 
(n = 8)
IHC 2+ 
(n = 4)
IHC 1+ 
(n = 22)
IHC 0 
(n = 69)
ALK FISH-positive (n = 12) 8 3 1 0
ALK FISH-negative (n = 91) 0 1 21 69
Seoul National University study: IHC (5A4) versus FISH study (κ = 0.92)38 
(28 ALK FISH positives out of 640 screened)
IHC 3+ 
(n = 16)
IHC 2+ 
(n = 10)
IHC 1+ 
(n = 14)
IHC 0 
(n = 413)
Test set (19 ALK FISH positives out of 453 tumors screened)
  ALK FISH-positive (n = 19) 16 3 0 0
  ALK FISH-negative (n = 434) 0 7 14 413
IHC 3+ 
(n = 6)
IHC 2+ 
(n = 6)
IHC 1+ 
(n = 2)
IHC 0 
(n = 173)
Validation set (9 ALK FISH out of 187 tumors screened)
  ALK FISH-positive (n = 9) 6 3 0 0
  ALK FISH-negative (n = 178) 0 3 2 173
Abbreviations: ALK, anaplastic lymphoma kinase; κ, interobserver variability; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NSCLC, non-small cell 
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Ongoing clinical development  
of crizotinib
Phase i trials
COG-ADVL0912 (NCT00939770) is an ongoing Children’s 
Oncology Group Phase I/II study of crizotinib to determine 
the maximum dose that is safe and tolerable and to obtain pre-
liminary information on clinical activity in pediatric patients 
with relapsed/refractory solid tumors, primarily central 
nervous system tumors and anaplastic large cell lymphoma. 
A8081002 (NCT00965731) is a combination study of erlo-
tinib in combination with crizotinib in NSCLC with the inten-
tion of randomizing NSCLC patients to erlotinib ±   crizotinib 
in advanced NSCLC once the recommended Phase II dose 
level of the erlotinib-crizotinib combination is achieved. 
A8081006 (NCT01121575) is a similarly designed trial 
combining crizotinib with dacomitinib (PF0299804), a pan 
HER inhibitor, in NSCLC.
Phase ii
Crizotinib has been reported to result in excellent clini-
cal benefit and response in inflammatory myofibroblastic 
tumors40 and anaplastic large cell lymphoma41 in case report 
format. PROFILE 1013 (NCT01121588) is a Phase II trial 
that will further study the safety and potential clinical activity 
of crizotinib in patients with ALK rearrangement or mutation-
positive tumors other than NSCLC, such as anaplastic large 
cell lymphoma, inflammatory myofibroblastic tumors, and 
neuroblastoma in a systemic manner. The primary endpoint 
of PROFILE 1013 is overall response rate.
Other targets of crizotinib
Crizotinib was initially developed as a MET inhibitor. Once 
the maximal tolerated dose has been reached and the rec-
ommended Phase II dose determined from the first part of 
A8081001, it is planned to enroll 25 patients with tumors 
that harbor MET amplification or mutations. Crizotinib has 
demonstrated clinical activity in MET-amplified NSCLC,42 
MET-amplified gastroesophageal carcinoma,43 and MET-
amplified glioblastoma.44 Additionally, because of the 
evolutionary relatedness between ALK and ROS receptor 
tyrosine kinases,45 crizotinib has also been shown in vitro 
to be a potential ROS inhibitor.46 The current amendment to 
A8081001 allows for screening and testing of crizotinib in 
tumors with ROS rearrangement.
Future directions and newer agents
Resistance to tyrosine inhibitors invariably develops, and 
usually involves development of a gatekeeper mutation in 
the kinase domain, such as T315I in chronic   myelogenous 
  leukemia, and T790M in EGFR-mutated NSCLC.47 Similarly, 
a patient developed resistance to crizotinib after 5 months of 
treatment and molecular analyses revealed the resistant tumor 
harbored two acquired but independent mutations within the 
kinase domain of EML4-ALK, C1156Y, and the gatekeeper 
mutation L1196M. BaF3 cells engineered to express these 
two EML4-ALK mutations indicated that these mutants were 
resistant to crizotinib.48 In vitro assays have also identified the 
L1196M gatekeeper mutation to be the major mechanism of 
resistance to crizotinib.49 Of note, amplification of transloca-
tion in ALK is the intermediate step of the resistance process 
based on the in vitro assays, but so far has not been observed 
from rebiopsy of tumors from patients who progressed on 
crizotinib.47 A separate mutation, F1174L, has been described 
in a patient with an inflammatory myofibroblastic tumor and 
RANPB2-ALK translocation who progressed on crizotinib.50
In light of the identification of the gatekeeper mutation 
before crizotinib is approved, many “second-generation” 
ALK inhibitors are now or soon to be entered into early 
clinical development to try to overcome crizotinib resistance, 
especially the L1196M gatekeeper mutation. One of the best 
characterized compounds is AP26113 (ARIAD Pharmaceuti-
cals, Cambridge, MA), a small-molecule competitive inhibi-
tor of the ALK tyrosine kinase domain. Of note, AP26113 is 
not only ten times more active than crizotinib in inhibiting 
wild-type ALK but is a hundred times more potent than 
crizotinib in inhibiting the L1196M gatekeeper mutation. 
Importantly, AP26113 inhibits ALK L1196M at the same 
subnanomolar concentration as it inhibits wild-type ALK 
kinase (Table 6).49 Another second-generation ALK inhibitor, 
CH542802 (Chugai Pharmaceutical Co Ltd, Tokyo, Japan), 
is also reported to have strong inhibitory activity in both 
wild-type ALK and L1196M gatekeeper mutation-harboring 
cell lines.51 However, to date, the number of patients reported 
with identified resistance mechanisms to crizotinib remains 
extremely small (less than four so far) and therefore it is 
premature to say that the L1196M gate-keeper mutation will 
Table 6 Comparison of Ki between crizotinib and AP26113 for 
wild-type ALK and ALK with LII96M gate-keeper mutation49
Ki (nM)
ALK wild-type ALK (L1196M)
Crizotinib (PF02341066) 0.69 8.2
AP26113 0.09 0.08
Notes: K m  of  crizotinib  and  AP26113  using  HotSpot  kinase  (Ki)  determination 
studies by Reaction Biology Corporation (Malvern, PA). 
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be the most important mechanism of acquired resistance to 
crizotinib than other mechanisms that can bypass the ALK 
signaling pathway. Indeed, in vitro cell line experiments have 
demonstrated that activating the EGFR signaling pathway 
can confer resistance to crizotinib, and that a small subset 
of ALK-rearranged NSCLC also harbor activating EGFR 
mutations. This finding suggests that some patients with 
ALK-rearranged NSCLC may have intrinsic resistance to 
crizotinib.52 Complicating the matter ever further, another 
study has shown that different ALK mutations confer dif-
ferential resistance to structurally diverse ALK inhibitors. 
Therefore, it is of utmost importance to rebiopsy to allow 
repeat molecular profiling of ALK-rearranged tumors.53
Another important pathway involved in EML4-ALK signal-
ing is the Hsp family. EML4-ALK fusion protein is an aberrantly 
synthesized protein residing in the cytoplasm. Hsp are chaperone 
proteins involved in stabilizing the EML4-ALK fusion protein in 
the cytoplasm and sorting the substrates of EML4-ALK. Hsp90 
is one of the major members of the Hsp family.54 EML4-ALK is 
an Hsp90 client protein and coprecipitates with other members 
of the Hsp family, including Hsp90.55 The association between 
Hsp90 and EML4-ALK can be disrupted by an Hsp90 inhibitor. 
Inhibition of Hsp90 leads to rapid degradation of EML4-ALK 
within 3 hours, together with downstream signaling pathways in 
ALK-dependent H3122 NSCLC cell lines.55 Moreover, addition 
of Hsp90 inhibitors resulted in cell death in an ALK-dependent 
cell line, tumor regression in an EML4-ALK xenograft, and 
regression of lung adenocarcinoma in the EML4-ALK trans-
genic mouse. Most importantly, Hsp90 inhibitors lead to cell 
death in both crizotinib-sensitive and crizotinib-resistant ALK-
dependent cell lines,49,55 including NSCLC cell lines harboring 
the ALK L1196M gatekeeper mutation49 which provides another 
alternate pathway to overcome resistance to crizotinib. Indeed, 
Hsp90 inhibitors have demonstrated preliminary clinical activity 
in patients with ALK-rearranged NSCLC.56,57
Will crizotinib suffer the same  
fate as gefitinib in the US?
I raise this question not because crizotinib is an ineffective 
drug for patients with ALK-rearranged NSCLC. In oncologic 
drug development, to show clinical benefit, an investigational 
drug has to perform better in terms of survival or side effect 
profile than the current standard of care in order for the inves-
tigational drug to be approved. Crizotinib is one of the first 
oncogenic drugs approved for a specific molecular-enriched 
patient population based on its activity in that population. 
Crizotinib was conditionally approved in the US on August 
26, 2011, based on response rates of 50% from PROFILE 
1005 and 61% from the A8081001 trial. The approval lan-
guage states “... This approval is based on response rate. There 
are no data available demonstrating improvement in patient 
reported outcomes or survival with XALKORI”.30 This 
approval does not specify what line of crizotinib treatment 
should be used, meaning crizotinib could be used for first-line 
treatment of patients with advanced ALK-rearranged NSCLC. 
However, data from only 15 patients with ALK-rearranged 
NSCLC who received crizotinib as first-line treatment for 
their disease formed the clinical data submitted to the FDA 
(Table 1). Gefitinib, an EGFR tyrosine kinase inhibitor, was 
conditionally approved in the US in 2003 based also on 
response rates from two Phase II trials.58 However, gefitinib 
did not achieve significant improvement in overall survival 
when compared with placebo in second-line treatment in the 
randomized Phase III ISEL (IRESSA® Survival Evaluation 
in Lung Cancer) study (hazard ratio [HR] 0.89, P = 0.087),59 
which resulted essentially in the withdrawal of gefitinib from 
the US market. In retrospect, the major reason why the ISEL 
trial failed is because knowledge of the optimal target of the 
EGFR tyrosine kinase inhibitor was not well understood 
at the time of design of the ISEL study. Indeed, subgroup 
analysis of ISEL revealed that gefitinib was beneficial in 
Asians, with significant improvement in overall survival when 
compared with placebo (HR 0.66; P = 0.010),60 especially 
in never-smokers, females, and adenocarcinoma cases in the 
Asian subgroup, in which most patients are known to harbor 
activating EGFR mutations.
ALK-rearranged NSCLC is a molecularly defined sub-
group of NSCLC, but remains quite heterogeneous because 
there are many EML4-ALK fusion proteins and other fusion 
partners for ALK.17,18 Secondly, there is now emerging evi-
dence that ALK-rearranged NSCLC responds well to pem-
etrexed, which may be related to a lower level of thymidylate 
synthase, a target of pemetrexed, in the ALK-rearranged lung 
tumor.61,62 The frontline PROFILE 1014 (NCT01154140) 
trial is comparing pemetrexed-platinum combination therapy 
with crizotinib alone in untreated ALK-rearranged NSCLC. 
PROFILE 1014 is designed to detect a 50% improvement 
in progression-free survival from 6 to 9 months, with 85% 
power and a one-sided significance level of 0.025.
Maintenance pemetrexed is not allowed in PROFILE 1007, 
although the recently presented PARAMOUNT pemetrexed 
maintenance trial indicated that there is significant improve-
ment in progression-free survival with continuous pemetrexed 
maintenance after four cycles of pemetrexed/cisplatin com-
pared with best supportive care.63 The   progression-free survival 
from the start of cisplatin/pemetrexed to the end of pemetrexed Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Figure 4 Three scenarios where there is a 33% progression (as defined by Response Evaluation in Solid Tumor [RECIST]) can occur when the tumor is still significantly 
smaller than from baseline, especially with molecular targeted therapy.
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maintenance was 6.9 months.63 It is possible that patients with 
ALK-rearranged NSCLC may enjoy a long   progression-free 
survival even without pemetrexed maintenance, and the trial 
may not have been sufficiently powered to detect a statisti-
cal significance in progression-free survival. Because PFS 
is chosen as the primary endpoint for the front line trial, 
RECIST criteria will be used to determine “progression”. 
Disease progression by RECIST is usually defined as either the 
appearance of new metastatic lesions or cumulative in tumor 
measurement > 20% from the smallest measurement achieved 
or a combination of both. I have listed three potential scenarios 
where cumulative tumor measurement increased by 33% (thus 
satisfying RECIST criteria for disease progression). Scenario 
one, where there is no response to treatment and the tumor 
continues to grow (Figure 4A). Scenario two, where there is 
some shrinkage of the tumor in response to treatment but not 
enough to stratify RECIST criteria for partial response and then 
the tumor grows back to a pre-treatment baseline (Figure 4B). 
The scenario is characteristic of a response to chemotherapy. 
In scenario three there is a dramatic response to treatment 
but then the tumor starts to slowly grow back. However, it is 
still much smaller than pre-treatment baseline (Figure 4C). 
Scenario three is characteristic of a highly effective targeted 
therapy such as crizotinib. Therefore, patients whose disease 
continues to progress while on crizotinib may still continue to 
derive clinical benefit and thus using progression-free survival 
and RECIST criteria may not truly reflect the beneficial effect 
of a highly effective targeted therapy.
Conclusion
The identification of activating EGFR mutations in NSCLC 
heralded the molecularly targeted therapy era in NSCLC and led 
to successful demonstration of the superiority of EGFR tyrosine 
inhibitors over standard platinum-doublet chemotherapy as the 
first line treatment of NSCLC patients with EGFR activating 
mutations. The identification of resistance mechanisms of first-
generation EGFR tyrosine inhibitors several years later led to 
the rational development of second-generation EGFR tyrosine 
inhibitors.47 These principles have guided the development of 
crizotinib ever since ALK rearrangement was first reported in 
NSCLC in August 2007, and have led to the identification of 
a gatekeeper mutation in EML4-ALK that preceded the US 
approval of crizotinib by months. The discovery of ALK 
mutations is now guiding the rapid development of second-
  generation ALK inhibitors and Hsp90 inhibitors. This paradigm 
will likely guide the development of molecularly targeted 
therapy in NSCLC patients against other potential driver 
mutations, such as the V600E BRAF mutation.64,65
Finally, one of the important findings in the era of molecular 
targeted therapy is that the tumor underwent rapid and dramatic 
shrinkage within a short period of time.28 The current RECIST 
criteria used in all oncology trials was designed in the era of 
chemotherapy when massive tumor shrinkage was not common. 
However, one of the definitions of progression by RECIST is a 
20% increase in cumulative tumor diameter from the smallest 
aggregate measurement. Thus, the greater the amount of tumor 
shrinkage a targeted therapy achieves, the less the tumor has to 
regrow to be defined as disease progression by RECIST. Thus, 
in many cases of molecularly targeted therapy at the time of 
progression, the tumor is still significantly smaller than baseline 
(Figure 4c). Therefore, the RECIST criteria may not be the 
optimal criteria to assess a highly efficacious targeted therapy 
when progression-free survival is the primary endpoint.
In the future, clinical studies of molecularly targeted 
therapy should allow patients to continue on treatment if there 
is “continual clinical benefit” and the pace of progression is 
measured, which was the case in A8081001 and PROFILE 
1005. Indeed, at least 15 patients in the A8081001 study 
continued on treatment after progression defined by RECIST 
because of “continual clinical benefit”.27
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